Sweet-P inhibition of glucocorticoid receptor β as a potential cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The increasing prevalence of drug-resistant cancers necessitates novel therapeutic strategies.
• Genomic advancements have improved cancer therapy, prevention, and early detection.
• Glucocorticoid receptor β (GRβ) is upregulated in various solid and liquid tumors, as well as in glucocorticoid-resistant asthma.

Purpose of the Study:

• To introduce Sweet-P, a novel molecule designed for targeted cancer therapy.
• To investigate Sweet-P's mechanism of action, focusing on its interaction with GRβ.
• To evaluate the therapeutic potential of Sweet-P in GRβ-related diseases.

Main Methods:

• Development of Sweet-P, a molecule targeting the microRNA-144 binding site in the 3' untranslated region of human GRβ.
• Assessment of GRβ expression in various cancer types and non-cancerous diseases.
• Evaluation of Sweet-P's efficacy in repressing cancer cell migration, specifically in bladder cancer.

Main Results:

• Sweet-P is identified as the first molecule to specifically target the GRβ binding site.
• High GRβ expression is confirmed in urothelial carcinomas, gliomas, osteosarcomas, hepatocellular carcinomas, and leukemia.
• Sweet-P demonstrated the ability to repress the migration of bladder cancer cells.

Conclusions:

• Sweet-P represents a pioneering therapeutic approach for targeting GRβ.
• The molecule shows promise as a new treatment for GRβ-associated cancers.
• Sweet-P may also offer therapeutic benefits for other GRβ-related conditions, such as glucocorticoid-resistant asthma.